Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03697564 |
| Title | Nivolumab + Cabiralizumab + Gemcitabine Versus Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial). |
| Recruitment | Suspended |
| Gender | both |
| Phase | FDA approved |
| Variant Requirements | No |
| Sponsors | Hitendra Patel |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |